USA – Blueprint Medicines, a US-based biotech that specializes in targeted cancer drugs, is set to pay US$250 million in cash and another US$215 million in potential milestone payments to…
Read MoreBlueprint Medicines expands oncology portfolio by acquiring Lengo Therapeutics for US$465 million
